CELLDEX THERAPEUTICS INC
NASDAQ: CLDX (Celldex Therapeutics, Inc.)
Last update: 2 hours ago26.03
-0.37 (-1.40%)
| Previous Close | 26.40 |
| Open | 26.33 |
| Volume | 482,309 |
| Avg. Volume (3M) | 830,608 |
| Market Cap | 1,729,679,744 |
| Price / Sales | 685.37 |
| Price / Book | 2.98 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -9,027.19% |
| Diluted EPS (TTM) | -2.70 |
| Quarterly Revenue Growth (YOY) | 345.50% |
| Total Debt/Equity (MRQ) | 0.49% |
| Current Ratio (MRQ) | 21.67 |
| Operating Cash Flow (TTM) | -171.51 M |
| Levered Free Cash Flow (TTM) | -101.09 M |
| Return on Assets (TTM) | -16.88% |
| Return on Equity (TTM) | -23.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Celldex Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.32% |
| % Held by Institutions | 113.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kynam Capital Management, Lp | 30 Sep 2025 | 6,100,729 |
| Wellington Management Group Llp | 30 Sep 2025 | 5,800,003 |
| Fmr Llc | 30 Sep 2025 | 4,962,088 |
| Point72 Asset Management, L.P. | 30 Sep 2025 | 3,893,942 |
| Bellevue Group Ag | 30 Sep 2025 | 3,557,669 |
| Commodore Capital Lp | 30 Sep 2025 | 3,028,335 |
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 2,382,518 |
| Deep Track Capital, Lp | 30 Sep 2025 | 2,000,000 |
| Eventide Asset Management, Llc | 30 Sep 2025 | 1,859,095 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 1,300,436 |
| Pictet Asset Management Holding Sa | 30 Sep 2025 | 1,211,990 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 48.00 (Mizuho, 84.40%) | Buy |
| Median | 36.00 (38.30%) | |
| Low | 24.00 (Barclays, -7.80%) | Sell |
| Average | 36.00 (38.30%) | |
| Total | 1 Buy, 1 Sell | |
| Avg. Price @ Call | 26.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 17 Dec 2025 | 24.00 (-7.80%) | Sell | 25.77 |
| 11 Nov 2025 | 21.00 (-19.32%) | Sell | 24.37 | |
| Mizuho | 21 Oct 2025 | 48.00 (84.40%) | Buy | 27.91 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |